Bristol Abilify Safety Profile Will Be Focus; Novel Mechanism May Help
Executive Summary
Bristol-Myers Squibb and Otsuka will attempt to position Abilify as a safer atypical antipsychotic based in part on an apparently novel mechanism of action
You may also be interested in...
FDA Sides With Lilly; Seeks Class Warning On Antipsychotic Diabetes Risk
The comparative risk for diabetes among atypical antipsychotics needs further research, FDA says in a letter to six manufacturers requesting a diabetes and hyperglycemia warning across the class
FDA Sides With Lilly; Seeks Class Warning On Antipsychotic Diabetes Risk
The comparative risk for diabetes among atypical antipsychotics needs further research, FDA says in a letter to six manufacturers requesting a diabetes and hyperglycemia warning across the class
VA Antipsychotic Diabetes Risk Studies Continue; First Report Helps Zyprexa
The Department of Veteran's Affairs plans to conduct a study on the incidence of diabetes among patients receiving combination antipsychotic therapy as a follow up to its study of patients on monotherapy